Annotating STEAP1 regulation in prostate cancer with 89Zr immuno-PET.
New York City, United States. In J Nucl Med, 2014
UNLABELLED: Antibodies and antibody-drug conjugates targeting the cell surface protein 6 transmembrane epithelial antigen of prostate 1 (STEAP1) are in early clinical development for the treatment of castration-resistant prostate cancer (PCa).
A role for STEAP2 in prostate cancer progression.
Swansea, United Kingdom. In Clin Exp Metastasis, 2014
Of particular interest was six transmembrane epithelial antigen of the prostate (STEAP) 1 and STEAP 2 which was subsequently analysed further in prostate cancer tissue samples following optimisation of an RNA extraction method from laser captured cells isolated from formalin-fixed paraffin-embedded biopsy samples.
CBX7 modulates the expression of genes critical for cancer progression.
Napoli, Italy. In Plos One, 2013
RESULTS: We found that CBX7 negatively or positively regulates the expression of several genes (such as SPP1, SPINK1, STEAP1, and FOS, FOSB, EGR1, respectively) associated to cancer progression, by interacting with their promoter regions and modulating their transcriptional activity.
Ironing out cancer.
Winston-Salem, United States. In Cancer Res, 2011
Discoveries of the roles of ferroportin, hepcidin, lipocalin 2, and members of the six transmembrane epithelial antigen of the prostate (STEAP) and iron regulatory protein (IRP) families in cancer have provided specificity and molecular definition to the role of iron homeostasis in cancer growth and metastasis.